International Stem Cell Corporation's Chairman and CEO, Kenneth Aldrich will speak at the 3rd International Congress of NanoBiotechnology and Nanomedicine (NanoBio 2009) on June 23, 2009. Mr. Aldrich's presentation is entitled, "Stem Cells and Nanotechnology: Marriage or Myth". The conference will take place in San Francisco from June 22-24, 2009 www.ianano.org.
skip to main |
skip to sidebar
Wear the PRO-CURE Wristband for Stem Cell Research Awareness
Genetic Engineering & Biotechnology News
ShareThis
Visit ISCO, LLCT and LLSC Websites
ISCO Mobile App QR
Subscribe here to have this info delivered to you
International Stem Cell Corporation Company Profile
International Stem Cell Corporation's Fan Box
Ben's Stem Cell News
Are You Pro Stem Cell Research?
Wear the PRO-CURE Wristband for Stem Cell Research Awareness
Like this?
Check out the GEN Blog
Genetic Engineering & Biotechnology News
Networked Blogs
We Blog Alot
ClickTale
ontoplist
hotvsnot
Add website to quality directories This site is listed under Biotechnology Directory
Add International Stem Cell Corporation news to your RSS reader
Subscribe, Visit or Listen to ISCO's New Podcast Below
The answers are already there. We are just discovering them.
Translate This Blog
Feed Shark
International Stem Cell Corporation's Objectives
1. To create an abundant source of stem cells to meet the rapidly growing research and therapeutic demands of regenerative medicine.
2. To create stem cell lines from unfertilized eggs, which would have all the benefits of human embryonic stem cells, but are superior in their ability to eliminate or diminish immune rejection in the patient.
3. To create a methodology to “cross match” stem cells for transplant into individual patients and to build a true “Cell Bank” allowing for on-demand delivery of cells that could be matched to the patient’s own immune system and reduce or eliminate the need for immunosuppressant drugs.
2. To create stem cell lines from unfertilized eggs, which would have all the benefits of human embryonic stem cells, but are superior in their ability to eliminate or diminish immune rejection in the patient.
3. To create a methodology to “cross match” stem cells for transplant into individual patients and to build a true “Cell Bank” allowing for on-demand delivery of cells that could be matched to the patient’s own immune system and reduce or eliminate the need for immunosuppressant drugs.
Forward Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
-30-